| __timestamp | Blueprint Medicines Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 31844000 | 46425000 |
| Thursday, January 1, 2015 | 48588000 | 81491000 |
| Friday, January 1, 2016 | 81131000 | 94291000 |
| Sunday, January 1, 2017 | 144687000 | 121827000 |
| Monday, January 1, 2018 | 243621000 | 160524000 |
| Tuesday, January 1, 2019 | 331450000 | 200000000 |
| Wednesday, January 1, 2020 | 326860000 | 275000000 |
| Friday, January 1, 2021 | 601033000 | 328100000 |
| Saturday, January 1, 2022 | 477419000 | 463800000 |
| Sunday, January 1, 2023 | 427720000 | 565000000 |
| Monday, January 1, 2024 | 341433000 | 731100000 |
Unleashing the power of data
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Neurocrine Biosciences, Inc. and Blueprint Medicines Corporation have been at the forefront of this innovation race. From 2014 to 2023, these companies have consistently increased their research and development (R&D) investments, reflecting their commitment to pioneering new treatments.
Blueprint Medicines Corporation has shown a remarkable growth trajectory, with R&D expenses surging by over 1,200% from 2014 to 2021. However, Neurocrine Biosciences, Inc. has not lagged far behind, with a 1,100% increase in the same period. Notably, in 2023, Neurocrine Biosciences outpaced Blueprint Medicines, investing 32% more in R&D.
This data underscores the dynamic nature of the biotech industry, where strategic investments in innovation can lead to groundbreaking advancements and competitive advantages.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
AbbVie Inc. vs Blueprint Medicines Corporation: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development Investment: Blueprint Medicines Corporation vs ADMA Biologics, Inc.
Research and Development Expenses Breakdown: Blueprint Medicines Corporation vs Veracyte, Inc.